Overgaard S, Løkkegaard N, Scrøder S, Fugleberg S, Nielsen-Kudsk F
Pharmacol Toxicol. 1987 May;60(5):321-4. doi: 10.1111/j.1600-0773.1987.tb01518.x.
The pharmacokinetics of cefotaxime and its main metabolite des-acetyl-cefotaxime were studied after a single 1000 mg intravenous dose in 8 patients with end stage renal disease during peritoneal dialysis. Pharmacokinetic parameters were determined by iterative non-linear least squares regression analysis of plasma and dialysis fluid drug concentration curves. Biological half-life of cefotaxime ranged from 2.3 to 8.2 hours and total plasma clearance from 11 to 103 ml/min. (0.11 to 1.7 ml/min/kg b.wt). Only 1.4% to 4.2% of the intravenous dose of cefotaxime was distributed to the dialysis fluid. We conclude that the dosage of cefotaxime to uraemic patients adjusted to the renal function needs no further adjustment during peritoneal dialysis.
在8例终末期肾病患者进行腹膜透析期间，静脉注射单次1000mg剂量头孢噻肟后，研究了其药代动力学及主要代谢产物去乙酰头孢噻肟的药代动力学。通过对血浆和透析液药物浓度曲线进行迭代非线性最小二乘回归分析来确定药代动力学参数。头孢噻肟的生物半衰期为2.3至8.2小时，血浆总清除率为11至103ml/分钟（0.11至1.7ml/分钟/千克体重）。静脉注射剂量的头孢噻肟仅有1.4%至4.2%分布至透析液中。我们得出结论，在腹膜透析期间，根据肾功能调整后的尿毒症患者头孢噻肟剂量无需进一步调整。
